SciFi Futures
← Capabilities
Biotech & Medicine/Component technology

Durable transplant immune tolerance

Getting a recipient's immune system to accept a foreign or engineered organ indefinitely without lifelong immunosuppression.

State of the art

Gene-edited pig kidneys functioned in human recipients for up to 271 days before irreversible rejection (2025) while still requiring heavy immunosuppression; donor-cell-based tolerance protocols remain limited to small HLA-matched cohorts.

What’s blocking it
  • Chronic antibody-mediated rejection proceeds even under current immunosuppression
  • Tolerance protocols trade rejection risk for conditioning toxicity and graft-versus-host disease
  • No assay predicts which recipients can be safely weaned off drugs

Who’s working on it

  • Medeor TherapeuticsStartup

    Its Phase 3 MDR-101 trial left 15 of 20 HLA-matched living-donor kidney recipients functionally tolerant and off all immunosuppression two years after withdrawal, with no graft loss or GVHD (Am J Transplant, 2025)

  • Dixon KaufmanResearcher
    University of Wisconsin-Madison

    First author of the MDR-101 Phase 3 report (2025), the first randomised controlled demonstration of durable drug-free tolerance in kidney transplantation

  • Megan SykesResearcher
    Columbia Center for Translational Immunology

    Pioneered minimal-conditioning mixed chimerism and xenogeneic thymic transplantation for tolerance; awarded the 2025 Starzl Prize for the path to xenograft tolerance

  • Tatsuo KawaiResearcher
    Legorreta Center for Clinical Transplant Tolerance, Massachusetts General Hospital

    Runs the combined kidney and bone-marrow tolerance protocols across HLA barriers and operated on the 2025 engineered-porcine-kidney recipients

  • Sana BiotechnologyCompany

    Transplanted hypoimmune-engineered primary islet cells into a type 1 diabetes patient with no immunosuppression at all; the cells survived and produced insulin at six and twelve months (2025)

  • NIAID-funded network that has run the clinical tolerance trials in transplantation and autoimmunity for two decades, including the chimerism and withdrawal protocols

What to invest in

KindInvestmentScale
researchPrimate and clinical trials of chimerism and regulatory-cell protocols with drug-withdrawal endpoints and tolerance biomarkers$$$ $100M – $1B
researchImmune-monitoring assays that detect loss of tolerance before graft injury$$ $10M – $100M

Sci-fi concepts in reach

Autodoc medical podindirectEngineered organ-donor animalsgatingdirectResurrection of extinct speciesindirectWhole-body rejuvenation treatmentindirectOn-demand replacement organsdirectAI cybrid (AI persona in a grown human body)indirectIndustrial ectogenesis (hatcheries)indirectNexus-6 androids (replicants)indirectCruciform resurrection parasiteindirectCyborg body augmentationindirectResleeving (transferring a mind into a new body)indirect

Sources